The treatment of juvenile arthritis

Bibliography

• PETTY RE. Classification of childhood arthritis: a work in progress. Ballieres Chin. Rheumatol. (1998) 12(2):181–190.
   PubMedGoogle Scholar
• PETTY RE, SOUTHWOOD TR, BAUM J etal.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997.j Rheumatol. (1998) 25(10):1991–1994.
   Google Scholar
• ••The new classification criteria will allowfuture researchers to determine optimal therapy for each subtype of juvenile idiopathic arthritis.
   Google Scholar
• GARE BA: Juvenile arthritis - who gets it, where and when?: A review of current data on incidence and prevalence. Chin. Exp. Rheumatol. (1999) 17:367–374.
   PubMed Web of Science ®Google Scholar
• KROLL T, BARLOW JH, SHAW K: Treatment adherence in JRA- a review. Scam/. Rheumatol. (1999) 28:10–18.
   PubMedGoogle Scholar
• HAFNER R, TRUCKENBRODT H, SPAMER M: Rehabilitation in children with juvenile chronic arthritis. Ballieres Chin. Rheumatol. (1998) 12(2):329–361.
   PubMedGoogle Scholar
• LOVELL DJ, GIANNINI EH, BREWER EJJ: Time course of response to nonsteroidal antiinflammatory drugs in juvenile rheumatoid arthritis. Arthritis Rheum. (1984) 27:1433–1437.
   PubMedGoogle Scholar
• LINDSLEY CB: Uses of nonsteroidal anti-inflammatory drugs in paediatrics. AJDC (1993) 147:229–236.
   PubMedGoogle Scholar
• LEN C, HILARIO MO, KAWAKAMI E, TERRERI MT, BECKER DJ, GOLDENBERG J: Fagundes Neto U, Hepato-Castroenterology (1999) 46(26)991–996.
   Google Scholar
• SIMON LS, WEAVER AL, GRAHAM DYet al.: Anti-inflammatory and upper GI effects of celecoxib in rheumatoid arthritis. A randomised control trial. JAMA (1999) 282:1921.
   Google Scholar
• EMERY P, ZEIDLER H, KVEIN TK et aL:Celecoxib versus diclofenac in long-term management of RA: Randomised double blind comparison. Lancet (1999) 354:2106.
   PubMed Web of Science ®Google Scholar
• LANGMAN MJ, JENSEN DM, WATSON DJ et al.: Adverse upper GI effects of roficoxib compared with NSAIDs. JAMA (1999) 282:1929.
   PubMed Web of Science ®Google Scholar
• SIMON LS, PINCUS T, WHELTON A et al.: Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomised controlled JAMA (2000) 284(10):1247–1255.
   Google Scholar
• PADEH S, PASS WELL JH: Intraarticularcorticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum. (1998) 41(7):1210–1214.
   PubMedGoogle Scholar
• SHERRY DD, STEIN LD, REED AM, SCHANBERG LE, KREDICH DW: Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steriods. Arthritis Rheum. (1999) 42(11):2330–2334.
   PubMedGoogle Scholar
• KLEIN-GITELMAN MS, PACHMAN LM: Intravenous corticosteroids: adverse reactions are more variable than expected in children. I Rheumatol. (1998) 25:1995–2002.
   Google Scholar
• ACR TASK FORCE ON OSTEOPOROSIS GUIDELINES: Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Rheum. (1996) 39:1791–1801.
   PubMedGoogle Scholar
• CASSIDY JT: Medical management of children with juvenile rheumatoid arthritis. Drugs (1999) 58(5):831–850.
   PubMedGoogle Scholar
• CRONSTEIN B: Molecular therapeutics. Methotrexate and its mechanism of action Arthritis Rheum. (1996) 39:1791–1801.
   PubMedGoogle Scholar
• GIANNINI EH, BREWER EJ et al.: Methotrexate in resistant juvenile rheumatoid arthritis. N Engl. I Med. (1992) 326:1043–1049.
   PubMed Web of Science ®Google Scholar
• ••Double-blind placebo controlled study ofMTX in RA demonstrating a statistically significant improvement in the group treated with low-dose MTX.
   Google Scholar
• ONEL KB: Advances in the medical treatment of juvenile rheumatoid arthritis. Cun: Opin. Pediatr. (2000) 12:72–75.
   PubMedGoogle Scholar
• RAVELLI A, VIOLAS, RAMENGHI B, BELUFFI G, ZONTA LA, MARTINI A: Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. j PedMtr: (1998) 133:262–265.
   Google Scholar
• KREMER JM, ALACON GS, LIGHTFOOT RWJ et al.: Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum. (1994) 37:316–328.
   PubMed Web of Science ®Google Scholar
• GRONDIN C, MALLESON P, PETTY RE: Slow acting antirheumatic drugs in chronic arthritis of childhood. Semin. Arthritis Rheum. (1988) 18(1):38–47.
   PubMedGoogle Scholar
• ••Good overview of the early studies performed of DMARDs in JRA.
   Google Scholar
• BREWER EJ, GIANNINI EH, KUZMINA N etal.: Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: results of the USA-USSR double blind placebo-controlled trial. N Engl. I Med. (1986) 314:1269–1276.
   Google Scholar
• BREWER EJ, GIANNINI EH, BARKLEY E: Gold therapy in the management of juvenile rheumatoid arthritis. Arthritis Rheum. (1980) 23:404–411.
   PubMedGoogle Scholar
• MANNERS PJ, ANSELL BM: Slow actingantirheumatic drug use in systemic onset juvenile chronic arthritis. Pediatrics (1986) 77:99–103.
   PubMed Web of Science ®Google Scholar
• VAN ROSSUM MA, FISELIER TJ, FRANSSEN MJ etal.: Sulfasalazine in the treatment of juvenile chronic arthritis: a randomised, double blind placebo controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. (1998) 41(5):808–816.
   Google Scholar
• PRIEUR AM, PUISSON C, MANIGNEP, BORDIGON P GRISELLI C: Evaluation of d-penicillamine in juvenile chronic arthritis. Arthritis Rheum. (1985) 28(4):376–382.
   PubMedGoogle Scholar
• MOUY R, STEPHAN JL, PILLET P, HADDAD E, HUBERT P, PRIEUR AM: Efficacy of cyclosporine A in the treatment of the macrophage activation syndrome in juvenile arthritis: report of 5 cases. Pediatr. (1996) 129(5):750–754.
   Google Scholar
• MARCHIESONI A, CERAVOLO GP, BATTAFARANO N, ROSSETTI A, TOSI S, FANTINI F: Cyclosporin A in the treatment of adult onset Stills disease. Rheumatol. (1997) 24:1582–1587.
   Google Scholar
• OSTENSEN M, HOYERAAL HM, KASS E: Tolerance of cyclosporine A in children with refractory JRA. I Rheumatol. (1988) 15:1536–1538.
   Google Scholar
• KVEIN TR, HOYERAAL HM, SANDSTAD B: Azathioprine versusplacebo in patients with juvenile rheumatoid arthritis: a single centre double blind comparative study. I Rheumatol. (1986) 13(1):118–123.
   Google Scholar
• SAVOLAINEN HA, KAUTIAINEN H, ISOMALII H, AHO K, VERRONEN P: Azathioprine in patients with juvenile rheumatoid arthritis: a long term follow-up study. J. Rheumatol. (1997) 24(12):2444–2450.
   PubMedGoogle Scholar
• WALLACE CA: On beyond methotrexate treatment of severe juvenile rheumatoid arthritis. Clin. Exp. Rheumatol (1999) 17:499–504.
   PubMed Web of Science ®Google Scholar
• MANGGE H, KENZIAN H, GALLISTL S etal.: Serum cytokines in JRA: Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum. (1995) 38:211–220.
   Google Scholar
• EBERHARD BA, LAXER RIVI, ANDERSSON U, SILVERMAN ED: Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with JRA. Clin. Exp. Immunol. (1994) 96:260–266.
   PubMedGoogle Scholar
• LOVELL DJ, GIANNINI EH, REIFF A et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl. j Med. (2000) 342:763–769.
   PubMed Web of Science ®Google Scholar
• ••Largest study to date of the new biologicaltherapies in children with JRA.
   Google Scholar
• LAHDENNE E HONKANEN V: Infliximab versus etatercept in the treatment of severe juvenile chronic arthritis. Arthritis Rheum. (2000) 43(Suppl.):Abstract 1888.
   Google Scholar
• GERSHON S, WISE RE NUI M, ROCKVILLE JS: Post licensure reports of infection during use of etanercept and infliximab. Arthritis Rheum. (2000) 43(Suppl.):Late breaking abstract.
   Google Scholar
• SILVERMAN ED, CAWKWELL GD, LOVELL DJ etal.: Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomised placebo controlled trial. Paediatric rheumatology collaborative study group. j Rheumatol (1994) 21:2353–2358.
   Google Scholar
• GIANNINI EH, LOVELL DJ, SILVERMAN ED, SUNDEL R1 TAGUE BL, RUPERTO N: Intravenous immunoglobulin in the treatment of polyarthicular juvenile rheumatoid arthritis: A Phase I/II study. Pediatric Rheumatology Collaborative Study Group. I Rheumatol (1996) 23(5):919–924.
   Google Scholar
• SNOWDON JA, BROOKS PM: Hematopoitic stem cell transplantation in rheumatic diseases. Curr. Opin. Rheum. (1999) 11:167–172.
   PubMedGoogle Scholar
• WULFFRAAT MN, BRINKMAN D, PRIEUR A, TEN CATE RC, VAN DER NET JJ, KAMPHUIS SSM: Autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Arthritis Rheum. (2000) 43(Suppl.):Abstract 1889.
   Google Scholar
• REIFF A, RAWLINGS DJ, SHAHAM B et al.: Preliminary evidence for cyclosporine A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. j Rheumatol (1997) 24:2436–2443.
   PubMed Web of Science ®Google Scholar
• FURST DE, WEAVER A, STRAND V: A comparison of leflunomide, placebo and methotrexate for the treatment of rheumatoid arthritis: A randomised, double blind multicentre study. Ann. Rheum. Dis. (1999) 58(EULAR Suppl.):Abstract 398.
   Google Scholar
• SMOLEN JS, SCOTT DL, KALDEN JR etal.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active RA: a double blind, randomised multicentre trial. Lancet (1999) 353:259–266.
   Google Scholar
• SCHNEIDER R, LAXER RM: Systemic onset juvenile RA. Ballieres Clin. Rheumatol (1998) 12:245–271.
   PubMed Web of Science ®Google Scholar
• SAVOLAINEN HA: Chlorambucil in severe juvenile chronic arthritis: Long term follow up with special reference to amyloidosis. I Rheumatol (1999) 26:898–903.
   Google Scholar
• DAVID J, VOUYIOUKA D, ANSELL BM, HALL A, WOO P: Amyloidosis in juvenile chronic arthritis a morbidity and mortality study. OM. Exp. Rheumatol (1993) 11(1):85–90.
   PubMed Web of Science ®Google Scholar
• ••Although retrospective provides usefullong-term efficacy:toxicity data.
   Google Scholar
• DOLLFUS H: Eye involvement in childrens rheumatic diseases. Ballieres Rheumatol. (1998) 12:309–328.
   PubMedGoogle Scholar
• SMITH JR, LEVINSON RD, HOLLAND GN et al: A differential efficacy of TNF inhibition in the treatment of inflammatory eye disease and associated rheumatological disease. Arthritis Rheum. (2000) 43(Suppl.) Abstract 1395.
   Google Scholar
• PEREIRA RMR, CORRENTE JE, CHATIADE WH, YOSHINARA NH: Evaluation by dual x-ray absorptiometry (DXA) of bone mineral density in children with juvenile chronic arthritis. OM. Exp. Rheum. (1998) 16:495–501.
   PubMedGoogle Scholar
• CASSIDY JT, HILLMAN LS: Abnormalities in skeletal growth in children with juvenile rheumatoid arthritis. Rheum. Dis. Clin. N Amer. (1997) 23(3):499–522.
   PubMedGoogle Scholar
• JOHNSTON CC, MILLER JZ, SLEMENDA CW: Calcium supplementation and increases in bone ineral density in children. N Engl. I Med. (1992) 327:82–87.
   PubMed Web of Science ®Google Scholar
• ROONEY M, DAVIES UM, REEVE J, PREECE M, ANSELL BM, WOO P: Bone mineral content and bone mineral metabolism) changes after growth hormone treatment in juvenile chronic arthritis. Rheumatol (2000) 27(4):1073–1081.
   Google Scholar
• BIANCHI ML, CIMAZ R, BARDARE M et al.: Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicentre study. Arthritis Rheum. (2000) 43(9):1960–1966.
   PubMed Web of Science ®Google Scholar
• BRUMSEN C, HAMDY NA, PAPAPOULOS SE: Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (1997) 76(4)266–283.
   Google Scholar
• GLORIEUX FH, BISHOP NJ, PLOTKIN H, CHABOT G, LAN OUE G, TRAVERS R: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta N Engl. J. Med. (1998) 339(14):947–952.
   Google Scholar
• WHITE PH: Juvenile Chronic Arthritis. In: Rheumatology (Edition 2). Klippel and Dieppe (Eds.), Mosby (1998).
   Google Scholar